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Abstract B-type natriuretic peptide (BNP) and C-type
natriuretic peptide (CNP), and (Cys-18)-atrial natriuretic
factor (4–23) amide (C-ANF), are cytoprotective under
conditions of ischemia–reperfusion, limiting infarct size.
ATP-sensitive K? channel (KATP) opening is also cardio-
protective, and although the KATP activation is implicated
in the regulation of cardiac natriuretic peptide release, no
studies have directly examined the effects of natriuretic
peptides on cardiac KATP activity. Normoxic cardiomyo-
cytes were patch clamped in the cell-attached configuration
to examine sarcolemmal KATP (sKATP) activity. The KATP
opener pinacidil (200 lM) increased the open probability
of the patch (NPo; values normalized to control) at least
twofold above basal value, and this effect was abolished by
HMR1098 10 lM, a selective KATP blocker (5.23 ± 1.20
versus 0.89 ± 0.18; P \ 0.001). We then examined the
effects of BNP, CNP, C-ANF and 8Br-cGMP on the sKATP
current. Bath application of BNP (C10 nM) or CNP
(C0.01 nM) suppressed basal NPo (BNP: 1.00 versus
0.56 ± 0.09 at 10 nM, P \ 0.001; CNP: 1.0 versus
0.45 ± 0.16, at 0.01 nM, P \ 0.05) and also abolished the
pinacidil-activated current at concentrations C10 nM.
C-ANF (C10 nM) enhanced KATP activity (1.00 versus
3.85 ± 1.13, at 100 nM, P \ 0.05). The cGMP analog
8Br-cGMP 10 nM dampened the pinacidil-activated
current (2.92 ± 0.60 versus 1.53 ± 0.32; P \ 0.05).
Natriuretic peptides modulate sKATP current in ventricular
cardiomyocytes. This may be at least partially associated
with their ability to augment intracellular cGMP concen-
trations via NPR-A/B, or their ability to bind NPR-C with
high affinity. Although the mechanism of modulation
requires elucidation, these preliminary data give new
insights into the relationship between natriuretic peptide
signaling and sKATP in the myocardium.
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Introduction
The natriuretic peptides are a family of structurally related
mediators with diverse autocrine/paracrine and endocrine
functions in multiple tissues but they are especially
involved in cardiovascular homeostasis [6, 31]. In the cir-
culation, C-type natriuretic peptide (CNP), which is pre-
dominantly of vascular origin under normal physiological
conditions, exerts autocrine/paracrine actions that are well
characterized in the vessel wall [33]. The cardiac-derived
atrial natriuretic peptide (ANP) and B-type natriuretic
peptide (BNP) exert pressure- and volume-regulating roles,
which may be viewed as classic endocrine functions [31].
However, there is extensive evidence that ANP and BNP
also exert multiple autocrine/paracrine actions within car-
diac tissue [6]. These local cardiac actions may be partic-
ularly important under pathological conditions when there
is enhanced release of ANP and BNP from tissue stores
[40]. These include conditions associated with pressure or
volume overload, cardiac remodeling and hypoxia where
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the peptides may exert fundamental (counter-) regulatory
actions within myocardium [17, 28, 40, 45].
Limited pharmacological evidence suggests a role of
ATP-sensitive K? channel (KATP) opening since protec-
tion is lost in the presence of the channel blockers gli-
benclamide and sodium 5-hydroxydecanoate [5]. This
latter mechanism is little understood. Of particular inter-
est, in pancreatic islet b cells, ANP exerts an insulino-
trophic action, associated with KATP blockade [36, 43].
Furthermore, inwardly rectifying K? channel 6.2 (Kir6.2)
deficient mice were demonstrated to be more susceptible
to stretch-induced ANP release compared to wild type,
suggesting a negative feedback axis between KATP and
cardiac natriuretic peptide release [38]. These findings are
intriguing as they suggest a plausible regulatory rela-
tionship between natriuretic peptides and KATP in distinct
endocrine secretory glands and specialized endocrine
organs [36, 38]. It is noteworthy that both cardiac and
pancreatic KATP contain the Kir6.2 core. However, they
differ with respect to the sulphonylurea receptor (SUR),
with Kir6.2 coupled to SUR2A in cardiomyocytes and to
SUR1 in pancreatic beta cells 1:1 tetrameric stoichiome-
try [1, 39].
In view of the increasing interest in the roles and ther-
apeutic potential of natriuretic peptides in cardiac disease,
it is important to characterize the actions of natriuretic
peptides on KATP function in cardiomyocytes. As such, this
study provides the first comprehensive and comparative
electrophysiological investigation of natriuretic peptides on
cardiac sarcolemmal KATP (sKATP) activity. After charac-
terizing sKATP activity in adult rat ventricular cardiomyo-
cytes, we sought to test the hypothesis that natriuretic
peptides promote sKATP opening by observing the effects
of BNP and CNP together with the natriuretic peptide
clearance receptor (NPR-C) agonist (Cys-18)-atrial natri-
uretic factor (4–23) amide (C-ANF) on sKATP activity in
these cells. Our data provide a characterization of the
actions of natriuretic peptides on sKATP. They strongly
suggest that, rather than activating sKATP, BNP and CNP at
physiological concentrations, and at supraphysiological
concentrations relevant to circulating plasma levels in
cardiac disease and therapeutic use, inhibit the ion channel.
They also suggest that the inhibition seen with BNP and




We used a total of 64 adult male Sprague–Dawley rats
(270–350 g, Harlan Laboratories Bicester, Oxford) for this
study. Their care and use were in accordance with UK
Home Office Guidelines on the Animals (Scientific Pro-
cedures) Act 1986 (The Stationary Office, London, UK).
Following pentobarbital anesthesia, hearts were excised
and left ventricular cardiac myocytes were isolated using a
standard enzymatic digestion protocol. Myocytes were
seeded at a density of 20,000 rods/well on extracellular
matrix gel-coated plastic coverslips, and cultured overnight
under normal CO2 incubator conditions at 37 C, prior to
treatments and patch clamping. See online resource for full
details.
Electrophysiology
The bath solution was in mM: 150 NaCl, 3 KCl, 10
D-glucose, 10 HEPES, pH 7.2. The recording pipette con-
tained in mM: 5 NaCl, 140 KCl, 1 MgCl2, 1 CaCl2, 11
EGTA, 10 HEPES, pH 7.2. During the sKATP channel
characterization phase of this study (see series 1), pipette
solutions containing KCl 70 mM:NaCl 70 mM (NaCl,
70 mM equimolar substitution) and KCl 200 mM were
used as comparator to the standard pipette solution. An
Axon CV-4 patch clamp headstage (Axon Instruments,
USA) was mounted on a three axis hydraulic microma-
nipulator (Narashige, Japan). Signals were amplified using
an Axopatch 1D patch clamp amplifier (Axon Instruments,
USA) and Neurolog DC amplifier (Digitimer Ltd., UK),
and digitized using a National Instruments BNC 2110
digitizer. Signals were typically filtered at 5 kHz and
sampling rate was 20 kHz. Signals were visualized on an
OX722 METRIX oscilloscope (ITT instruments) or com-
puter screen.
Electrodes were pulled from filamented borosilicate
glass capillaries (1.5/0.86 OD and ID, respectively; Har-
vard Apparatus, UK) and fine polished using a DMZ
Universal Puller (Zeitz-Instrumente, Germany). Micro-
electrodes had resistances of 5–10 MX.
Single channel recordings were made from cell-attached
patches, and performed at room temperature 22–24 C, as
our setup does not contain a Peltier thermoelectric device
for cooling and heating. The electrophysiological gating
properties of adult rat cardiac KATP do not significantly
change at temperatures ranging 20–30 C [26]. In an
independent study, Kohlhardt and colleagues observed a
consistent but slight increase in neonatal rat cardiac KATP
activity at temperatures ranging 29–39 C compared to
19–29 C [21].
Following gigaohm seal formation, currents passing
through single ion channels were observed and recorded.
Recordings (45 s) were made over a range of patch
potentials: 0, -30, -60, -90, and -120 mV. The
parameter NPo, where N is the number of channels in the
patch and Po the open probability of one channel, was used
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to determine the effects of different compounds and
natriuretic peptides on KATP activity. Po is derived from
the sum of individual channel opening times (O) and
individual closed times (C), thus Po = O/(O ? C).
WinEDR v3.2.2 software (Strathclyde University, UK) was
used for data acquisition and single channel analysis.
Materials
Rat BNP-(1–32) and C-ANF-(4–23) were obtained from
Sigma-Aldrich UK, and both CNP-(1–22) and 8Br-cGMP
from Tocris bioscience UK. sKATP channel opener pinac-
idil (Sigma-Aldrich, UK) was dissolved in dimethylsulf-
oxide (DMSO; maximal final concentration of 0.25 % v/v).
HMR1098, a selective sKATP inhibitor, was the kind gift of
Dr Ju¨rgen Pu¨nter, Sanofi-Aventis Germany. With the
exception of HMR1098, all compounds were diluted in
bath solution (see recording solutions); HMR1098 was
diluted in unsupplemented medium 199.
Treatments
The number of cells patched is shown in brackets. All cells
from group 4 onwards were patched with KCl 140 mM in
the patch pipette. All treatments were randomized.
Series 1
In these experiments, we sought to characterize the ion
selectivity and conductance of sKATP, thus cells were
patched using different concentrations of KCl with or in the
absence of NaCl, which was used as an equimolar sub-
stitute (group 1–3). In addition, long established and
experimentally characterized KATP modulators were used
to pharmacologically test whether the channel observed in
our patch clamp recordings is sKATP (group 4–7).
Ion selectivity experiments
Group 1, KCl 70 mM and NaCl 70 mM (n = 4)
Group 2, KCl 140 mM (n = 5)
Group 3, KCl 200 mM (n = 4)
sKATP channel modulation experiments
Group 4, control (n = 12): cells were pretreated with
unsupplemented medium 199 for 30 min, then patch
clamped in bath solution, or in bath solution containing
DMSO 0.25 % v/v.
Group 5, pinacidil 200 lM (n = 7): cells were pre-
treated with unsupplemented medium 199 for 30 min, then
patch clamped following bath application of pinacidil.
Group 6, HMR1098 10 lM (n = 8): cells were pre-
treated with HMR1098 in unsupplemented medium 199 for
30 min, then patch clamped in bath solution, or in bath
solution containing DMSO 0.25 % v/v.
Group 7, HMR1098 ? pinacidil (n = 6): cells were
pretreated with HMR1098 in unsupplemented medium 199
for 30 min, then patch clamped following bath application
of pinacidil.
Series 2
These experiments were designed to examine the effect of
natriuretic peptides on sKATP channel activity and con-
ductance. Cells were patched clamped in bath solution
containing BNP, CNP or C-ANF, in the absence or in the
presence of pinacidil. All natriuretic peptides were applied
at six concentrations ranging from 0.01 to 1,000 nM. Two
independent sets of experiments were done for low con-
centrations (0.01, 0.1 and 1 nM) and high concentrations
(10, 100 and 1,000 nM) of BNP and CNP, with each series
having their own separate control and pinacidil treatment
groups, respectively. Experiments with C-ANF were done
as a single set.
The effect of BNP on sKATP activity
Set 1: the effect of low concentrations of BNP on sKATP
activity
Group 8, control (n = 8): cells were patched clamped in
bath solution, or in bath solution containing DMSO 0.25 %
v/v.
The following compounds were bath applied:
Group 9, pinacidil 200 lM (n = 10)
Group 10, BNP 0.01 nM (n = 5)
Group 11, BNP 0.1 nM (n = 3)
Group 12, BNP 1 nM (n = 5)
Group 13, BNP 0.01 nM ? pinacidil (n = 3)
Group 14, BNP 0.1 nM ? pinacidil (n = 5)
Group 15, BNP 1 nM ? pinacidil (n = 3)
Set 2: the effect of high concentrations of BNP on sKATP
activity
Group 16, control (n = 35): cells were patched clamped
in bath solution, or in bath solution containing DMSO
0.25 % v/v.
The following compounds were bath applied:
Group 17, pinacidil 200 lM (n = 41)
Group 18, BNP 10 nM (n = 9)
Group 19, BNP 100 nM (n = 8)
Group 20, BNP 1,000 nM (n = 14)
Group 21, BNP 10 nM ? pinacidil (n = 9)
Group 22, BNP 100 nM ? pinacidil (n = 8)
Group 23, BNP 1,000 nM ? pinacidil (n = 10)
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The effect of CNP on sKATP activity
Set 1: the effect of low concentrations of CNP on sKATP
activity
Group 24, control (n = 5): cells were patched clamped
in bath solution, or in bath solution containing DMSO
0.25 % v/v.
The following compounds were bath applied:
Group 25, pinacidil 200 lM (n = 4)
Group 26, CNP 0.01 nM (n = 3)
Group 27, CNP 0.1 nM (n = 3)
Group 28, CNP 1 nM (n = 3)
Group 29, CNP 0.01 nM ? pinacidil (n = 4)
Group 30, CNP 0.1 nM ? pinacidil (n = 3)
Group 31, CNP 1 nM ? pinacidil (n = 4)
Set 2: the effect of high concentrations of CNP on sKATP
activity
Group 32, control (n = 29): cells were patched clamped
in bath solution, or in bath solution containing DMSO
0.25 % v/v.
The following compounds were bath applied:
Group 33, pinacidil 200 M (n = 34)
Group 34, CNP 10 nM (n = 10)
Group 35, CNP 100 nM (n = 9)
Group 36, CNP 1,000 nM (n = 16)
Group 37, CNP 10 nM ? pinacidil (n = 8)
Group 38, CNP 100 nM ? pinacidil (n = 8)
Group 39, CNP 1,000 nM ? pinacidil (n = 8)
The effect of low and high concentrations of C-ANF
on sKATP activity
Group 40, control (n = 7): cells were patched clamped in bath
solution, or in bath solution containing DMSO 0.25 % v/v.
The following compounds were bath applied:
Group 41, pinacidil 200 lM (n = 11)
Group 42, C-ANF 0.01 nM (n = 6)
Group 43, C-ANF 0.1 nM (n = 3)
Group 44, C-ANF 1 nM (n = 5)
Group 45, C-ANF 0.01 nM ? pinacidil (n = 7)
Group 46, C-ANF 0.1 nM ? pinacidil (n = 4)
Group 47, C-ANF 1 nM ? pinacidil (n = 7)
Group 48, C-ANF 10 nM (n = 5)
Group 49, C-ANF 100 nM (n = 4)
Group 50, C-ANF 1,000 nM (n = 5)
Group 51, C-ANF 10 nM ? pinacidil (n = 4)
Group 52, C-ANF 100 nM ? pinacidil (n = 4)
Group 53, C-ANF 1,000 nM ? pinacidil (n = 6)
Series 3
cGMP generation is the common second messenger signal
following receptor stimulation by BNP and CNP. These
experiments examined if 8Br-cGMP, a cell-permeable
analog of cGMP, could mimic the effects of these
peptides.
The effect of cGMP on sKATP activity
Group 54, control (n = 18): cells were patched clamped in
bath solution, or in bath solution containing DMSO 0.25 %
v/v.
The following compounds were bath applied:
Group 55, pinacidil 200 lM (n = 12)
Group 56, 8Br-cGMP 10 nM (n = 10)
Group 57, 8Br-cGMP ? pinacidil (n = 14)
PCR and western blotting
Gene and protein expression of KATP channel subunits
were determined in myocardial tissue extracts by RT-PCR
and Western blotting. See online resource for full
descriptions.
Data analysis
Data are expressed as mean ± standard error of the mean
(SEM). Ion channel open probabilities (NPo) are normal-
ized to control. Raw data corresponding to specific treat-
ment groups were compared for statistical significance
using Dunnett’s or Newman-Keuls’ multiple comparison
tests following one-way analysis of variance (ANOVA).
Differences between arithmetic means were considered
significant when P \ 0.05. Data were analyzed using
GraphPad Prism 5 software (GraphPad software Inc.,
USA).
Results
sKATP channel composition revealed by PCR
and Western blotting
We confirmed the expression of all KATP subunits at the
gene and protein level (Figs. 1, 2) in at least three out of
four ventricular myocardial samples analyzed. Strong gene
expression was evident for all subunits in all samples
analyzed; furthermore, Kir6.1, Kir6.2, SUR1 and SUR2
subunit proteins were strongly expressed. These expres-
sion patterns confirm the presence of all KATP subunit
proteins in the cardiomyocyte and indicate the possibility
that alternative KATP subunit configurations might be
present in the cardiac sarcolemma alongside the native
Kir6.2/SUR2A channel.
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sKATP electrophysiological characterization
Differing sKATP openings, unitary currents and conductance
states were observed in cell-attached patches for each patch
pipette configuration (Fig. 3a, b). Changes in KCl concen-
tration (70, 140 and 200 mM) and interpolation of current
voltage relationships yielded unitary conductances of
44.03 ± 1.38, 54.77 ± 1.83, and 61.31 ± 1.87 pS. An
increase in unitary conductance was seen when the concen-
tration of KCl in the patch pipette was increased, and the
changes observed were statistically significant (44.03 ± 1.38
versus 54.77 ± 1.83 pS, P \0.01; 61.31 ± 1.87 versus
54.77 ± 1.83 pS, P \ 0.05). The intermediary unitary
conductances are probably indicative of a functional chi-
meric sKATP with likely co-assembled pore forming subunits
of Kir6.1 and 6.2 coupled with SUR2A [12].
In preliminary experiments, pinacidil was selected as the
most consistently effective KATP opener. Bath application
of pinacidil 200 lM had a marked effect on channel
activity highlighted by a 5.2-fold increase in channel NPo
compared to control (Fig. 3c–e; P \ 0.001). In our hands,
there was no relationship between NPo and patch potential
change as illustrated in Figs. 3d, 4c, 5c, 6c and 7b. There
was no significant difference in sKATP unitary conductance
with pinacidil (P [ 0.05; see Table 1). The selective sKATP
inhibitor HMR1098 10 lM had no effect on basal channel
activity and NPo, P [ 0.05, but effectively reduced pi-
nacidil-induced sKATP openings and NPo (Fig. 3c–e) to
basal levels (83 % reduction; 5.23 ± 1.20 versus
Fig. 1 RT PCR amplification
of GAPDH and KATP pore
forming and receptor subunit
mRNA. Samples are from four
independent cardiomyocyte
isolations from rat left ventricle.
The gene coding for each KATP
subunit is clearly seen. All
samples were diluted in Novel
Juice (Genedirex, USA), a non-
mutagenic nucleic acid stain,
and were separated on the same
15 by 25 cm 1 % agarose gel
for 6 h prior to UV
transillumination and photo
aquisition. The following PCR
products were obtained, and the
gene and product size is shown
in brackets: GAPDH (223 bp),
Kir6.1 (KNCJ8, 227 bp), Kir6.2
(KNCJ11, 201 bp), SUR1
(ABCC8, 169 bp) and SUR2
(ABCC9, 228 bp)
Fig. 2 Western blots showing the protein expression of the KATP
pore forming and receptor subunits in cardiomyocytes isolated from
left ventricle. Samples consist of protein extracted from the same four
independent cardiomyocyte isolations as mentioned in the legend for
Fig. 1. Strong Kir6.2, SUR1 and SUR2 protein expression is seen,
whereas Kir6.1 expression is weak comparably. A 70 kDa band is
seen for SUR1 and not the predicted 177 kDa, but according to Pu
and colleagues [32], this could be a SUR1 short form splice variant.
The following amount of protein was loaded when probing for each
KATP subunit: 150 lg for Kir6.1, 80 lg for Kir6.2, and 100 lg for
SUR1 and SUR2
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0.89 ± 0.18; P \ 0.001). There was no significant differ-
ence in sKATP unitary conductance with HMR1098
(P [ 0.05; see Table 1).
The effect of BNP and CNP on sKATP opening
Neither BNP nor CNP caused an appreciable increase in
sKATP activity (Figs. 4a–e, 5a–e); in fact, bath application
of either peptide resulted in a decrease in channel activity.
BNP (C10 nM) and CNP (C0.01 nM) caused a significant
decrease in sKATP NPo compared to control (Figs. 4a–e,
5a–e). For BNP and CNP, this decrease was concentration
dependent (Figs. 4d, 5d). BNP at low concentrations
(B1 nM) had no effect on sKATP current and NPo (Fig. 4d).
When either BNP (C10 nM) or CNP (C10 nM) was applied
with pinacidil, the effects of the sKATP opener were com-
pletely abolished, highlighted by a marked reduction in
channel NPo down to or below basal level. This significant
effect was seen with BNP at all concentrations C10 nM
[Fig. 4e: 2.28 ± 0.28 versus 0.50 ± 0.08 (10 nM),
0.49 ± 0.07 (100 nM), 1.03 ± 0.13 (1,000 nM); P\0.001].
CNP at two out of three concentrations had similar
effects [Fig. 5e: 1.61 ± 0.20 versus 0.83 ± 0.15 (10 nM),
0.58 ± 0.10 (100 nM); P \ 0.05 and P \ 0.01, respec-
tively]. BNP (B1 nM) did reduce pinacidil-stimulated
sKATP currents but these effects did not reach significance
(Fig. 4e; P [ 0.05); furthermore, CNP applied at low con-
centrations (B1 nM) was incapable of inhibiting pinacidil-
stimulated sKATP currents (Fig. 5e; P [ 0.05). These
effects were not voltage dependent (Figs. 4c, 5c), and all
treatments (see Table 1) had no significant effect on single
channel unitary conductance compared to control.
The effect of C-ANF on sKATP activity
The NPR-C agonist C-ANF had interesting effects on sKATP
activity. C-ANF (0.01 and 1 nM) had a negligible sKATP NPo;
however, a 2.4-fold increase in NPo was seen with C-ANF
0.1 nM compared to control; however, this was not significant
(Fig. 6d; P[0.05). C-ANF (C10 nM) augmented sKATP
activity although a significant effect on sKATP NPo was only
seen with C-ANF 100 nM (Fig. 6d; P\0.01); nevertheless,
C-ANF 10 and 1,000 nM caused an appreciable increase in
sKATP activity (Fig. 6d). C-ANF 1 nM caused a significant
blunting of pinacidil stimulated sKATP currents (2.54 ± 0.6
versus 1.22 ± 0.29 (1 nM); P \0.05); however, this effect
was not seen at all the other concentrations tested (Fig. 6e). The
effects exhibited by C-ANF at all other concentrations were not
statistically significant, although modest dampening of pinac-
idil stimulated sKATP activity is still evident at some
Fig. 3 Representative sKATP recordings (a and c), current–voltage
plots (b), relationship between open probability and patch potential
change (d) and open probability histograms (e). Data are
mean ± SEM. ***P \ 0.001 versus control and ###P \ 0.001 versus
pinacidil (e), one-way ANOVA with Newman-Keuls post hoc test
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concentrations (Fig. 6e; P[0.05). There was no significant
effect on single channel unitary conductance compared to
control, and effects on NPo were not voltage dependent
(P [0.05; Fig. 6c and Table 1).
Cyclic GMP effect on sKATP activity
Unlike BNP and CNP, application of 8Br-cGMP (10 nM)
did not cause a significant decrease in basal sKATP activity
compared to control (P [ 0.05). However, the compound
attenuated sKATP responses to pinacidil when given
simultaneously, causing a reduction in NPo (Fig. 7c). This
50 % relative reduction in NPo was significant
(2.92 ± 0.60 versus 1.53 ± 0.32; P \ 0.05). There was no
appreciable effect on single channel conductance compared
to control, and effects on NPo were not voltage dependent
(P [ 0.05; Fig. 7b and Table 1).
Discussion
Principal findings
Our data confirm the existence and expression of all KATP
subunit genes and proteins in ventricular cardiomyocytes
using RT-PCR and Western blotting and patch clamping,
revealing a functional sKATP with biophysical and phar-
macological properties consistent with that reported in the
literature [46]. Our data also demonstrate a novel natri-
uretic peptide receptor mechanism of sKATP regulation in
the cardiomyocyte under normoxic conditions. BNP
(B1 nM) had no effect on basal sKATP current but at high
concentrations (C10 nM) inhibited the ion channel,
reducing NPo. BNP suppressed pinacidil-stimulated sKATP
currents at all concentrations with the most marked effect
seen at concentrations C10 nM. CNP (C0.01 nM)
Fig. 4 Representative sKATP recordings (a and b), the relationship
between open probability and patch potential change (c) and open
probability histograms (d and e). Data are mean ± SEM.
***P \ 0.001 versus control (d), one-way ANOVA with Dunnett
post hoc test; ***P \ 0.001 versus control and ###P \ 0.001 versus
pinacidil (e), one-way ANOVA with Newman-Keuls post hoc test
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suppressed basal sKATP openings, but only displayed this
inhibitory action in presence of pinacidil at concentra-
tions C10 nM. C-ANF (C10 nM) had a marked stimu-
latory effect on basal sKATP; however, the effects of
C-ANF at low concentrations (B1 nM) are inconsistent.
C-ANF had a negligible blunting effect on pinacidil-
stimulated sKATP currents at all concentrations except at
1 nM. The action of BNP and CNP could potentially be
associated with their ability to elevate intracellular con-
centrations of the second messenger cGMP, as it was
demonstrated that the analog 8Br-cGMP was capable of
dampening the pinacidil-activated sKATP current. As
complete speculation, the stimulatory action of C-ANF at
high concentrations (C10 nM) could be associated with
NPR-C mediated activation of PKC and subsequent
sKATP opening [2, 24, 37].
Biomolecular, biophysical and pharmacological
characterization of rat ventricular KATP
In this study, RT-PCR and Western blotting demonstrated
the presence of Kir6.1, Kir6.2, SUR1 and SUR2 genes and
proteins in rat left ventricular cardiomyocytes (Figs. 1, 2).
Using immunofluorescence microscopy, Morrissey and
colleagues confirmed the expression of all four KATP sub-
unit proteins in rat ventricular cardiomyocytes, observing
the co-localization of Kir6.2 and SUR2 subunits in the
sarcolemma and transverse t-tubules [27]. Additionally,
they found that Kir6.1 and SUR1 expression was particu-
larly strong at the sarcolemmal surface [27]. Concerning
the expression of SUR1 in our study, a strong band was
detected at 70 kDa rather than the predicted 174 kDa. It
is not known if the 70 kDa band was unmasked due to
Fig. 5 Representative sKATP recordings (a and b), the relationship
between open probability and patch potential change (c) and open
probability histograms (d and e). Data are mean ± SEM. *P \ 0.05
and ***P \ 0.001 versus control (d), one-way ANOVA with Dunnett
post hoc test; *P \ 0.01 versus control, #P \ 0.05 and ##P \ 0.01
versus pinacidil (e), one-way ANOVA with Newman-Keuls post hoc
test
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non-specific binding of the primary antibody, or if a SUR1
short form splice variant was detected. Splice variants of
SUR1 have already been described in the heart [14, 18, 32];
however, their biological significance requires further
elucidation.
The single channel unitary conductance of sKATP in
symmetrical K? (140 mM) conditions was between 50
and 60 pS (see Table 1). A sKATP was described in adult
rat ventricular cardiomyocytes with a unitary conductance
of 57.2 pS [46]. However, a considerable body of evi-
dence has reported the unitary conductance of KATP in
guinea pig [29], human [3], mouse [4], rabbit [29] and rat
[48] ventricular cardiomyocytes to be between 70 and
80 pS under similar experimental conditions. This dis-
parity in channel conductance reported in this study
compared to that historically reported can be explained
by the role of Kir6.X subunits in dictating KATP con-
ductance [34]. Kir6.1 and Kir6.2 are highly homologous
proteins that form a functional K? channel when coupled
to a SUR (1:1 tetrameric stoichiometry), with remarkably
different unitary conductance. Under symmetrical K?
conditions, Kir6.1/SURX and Kir6.2/SURX have a
divergent unitary conductance approximating 35 and
80 pS, respectively [34]. Chimeras of KATP have been
described as exhibiting an intermediary unitary conduc-
tance between 55 and 65 pS [4, 12, 25, 42]. In two
independent studies, the unitary conductance of KATP in
cardiac cells isolated from mouse and rabbit purkinje
fibers was demonstrated to be 57.1 pS [4] and 60.1 pS
[25], respectively. Bao and colleagues proposed that the
channel observed in their inside-out patch clamp experi-
ments was a chimeric KATP [4]. Intriguingly following
Fig. 6 Representative sKATP recordings (a and b), the relationship
between open probability and patch potential change (c) and open
probability histograms (d and e). Data are mean ± SEM. **P \ 0.01
versus control (d), one-way ANOVA with Dunnett post hoc test;
#P \ 0.05 versus pinacidil (e), one-way ANOVA with Newman-
Keuls post hoc test
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each attempted excision of the patch, channel activity
completely disappeared, and according to Bao and co-
workers, this could be indicative or a characteristic of a
heteromeric KATP [4]. Morrissey and co-workers put
forward the notion that a reassessment of the molecular
composition of KATP in ventricular myocytes is needed,
after elegantly showing strong sarcolemmal expression of
Kir6.1 and SUR1 subunits by means of immunofluores-
cence [27]. In light of all the evidence, it is possible that
a heteromeric KATP is present in the cardiac sarcolemma
that presumably comprised two pore forming subunits of
Kir6.1 and 6.2 coupled with SUR2A. This could explain
why in our hands, a sarcolemmal K? channel with fea-
tures associated with KATP with a unitary conductance
50–60 pS was evident in our cell-attached patches.
In cell-attached patches, sKATP activity was markedly
upregulated by the KATP opener pinacidil (Fig. 3c–e), an
effect not seen with diazoxide (data not shown). This
finding was not surprising because KATP with SUR1
(atrium) [14] and SUR2B (smooth muscle) [49] is highly
sensitive to diazoxide, but not the SUR2A form (ventricle)
[1]. Typically, pinacidil 200 lM increased sKATP NPo
several fold above basal, an effect that was completely
abolished by the selective inhibitor of the membrane form
of KATP HMR1098 10 lM (Fig. 3d, e). HMR1098 did not
reduce basal KATP openings (Fig. 3d, e). HMR1098 at
concentrations C100 lM would be sufficient to reduce
basal KATP opening [50]. These data provide pharmaco-
logical evidence that the K? channel observed in cell-
attached patches was sKATP.
Natriuretic peptide receptor modulation of rat
ventricular KATP
Application of both BNP (C10 nM) and CNP (C0.01 nM)
caused a marked and consistent depression of basal sKATP
activity and NPo (Figs. 4, 5), contrary to our thinking that
naturally occurring natriuretic peptides elicit/upregulate
sKATP opening. The rationale behind our hypothesis that
natriuretic peptides promote KATP opening was based on
several studies in the setting of cardioprotection, showing
that natriuretic peptide-induced limitation of infarct size
involves KATP opening [5, 13, 47]. Thus, this study initially
set out to investigate such a possibility by means of patch
Fig. 7 Representative sKATP recordings (a), the relationship between
open probability and patch potential change (b) and open probability
histograms (c). Data are mean ± SEM. ***P \ 0.001 versus control
and #P \ 0.05 versus pinacidil (c), one-way ANOVA with Newman-
Keuls post hoc test
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Table 1 Current voltage data, group number in round brackets
Treatment Number of cells Unitary conductance (pS) Reversal potential (mV) NPo
1 4 44.03 ± 1.38 52.69 ± 1.86 –
2 5 54.77 ± 1.83 52.91 ± 0.92 –
3 4 61.31 ± 1.87 55.06 ± 2.25 –
4 12 57.08 ± 3.10 46.71 ± 5.44 1.00
5 7 61.93 ± 5.37 52.42 ± 19.10 5.23 ± 1.20
6 8 60.94 ± 5.67 46.46 ± 8.97 0.92 ± 0.26
7 6 53.42 ± 6.15 82.24 ± 26.28 0.89 ± 0.18
8 8 59.61 ± 4.94 2.90 ± 11.47 1.00
9 10 56.78 ± 2.34 22.19 ± 7.46 2.55 ± 0.88
10 5 56.62 ± 4.13 29.30 ± 11.71 1.44 ± 0.28
11 3 57.93 ± 2.89 31.52 ± 19.94 1.14 ± 0.28
12 5 56.04 ± 4.56 7.96 ± 13.97 0.85 ± 0.16
13 3 45.93 ± 11.78 29.06 ± 13.75 0.41 ± 0.05
14 5 65.08 ± 6.40 7.19 ± 4.23 1.50 ± 0.30
15 3 52.70 ± 6.70 43.06 ± 5.35 1.10 ± 0.29
16 35 52.91 ± 1.66 26.11 ± 6.05 1.00
17 41 59.61 ± 1.96 34.98 ± 4.61 2.28 ± 0.28
18 9 53.83 ± 2.03 22.29 ± 12.70 0.56 ± 0.09
19 8 62.05 ± 6.84 32.84 ± 12.66 0.29 ± 0.06
20 14 56.69 ± 4.47 50.97 ± 7.75 0.65 ± 0.28
21 9 66.41 ± 5.32 37.41 ± 8.90 0.50 ± 0.08
22 8 55.75 ± 2.52 50.73 ± 4.75 0.49 ± 0.28
23 10 51.48 ± 2.92 50.55 ± 5.80 1.03 ± 0.13
24 5 62.92 ± 4.08 21.11 ± 14.10 1.00
25 4 69.8 ± 4.87 7.73 ± 13.09 2.08 ± 0.50
26 3 58.13 ± 12.26 -1.96 ± 30.88 0.45 ± 0.16
27 3 61.57 ± 5.89 30.93 ± 23.62 0.57 ± 0.20
28 3 67.47 ± 1.69 33.42 ± 23.41 0.47 ± 0.14
29 4 45.93 ± 11.78 29.06 ± 13.75 1.76 ± 0.62
30 3 65.08 ± 6.40 7.19 ± 4.23 2.05 ± 0.54
31 4 52.70 ± 4.70 43.06 ± 5.35 3.05 ± 0.84
32 29 52.07 ± 2.03 25.61 ± 7.01 1.00
33 34 58.53 ± 2.33 29.91 ± 4.90 1.61 ± 0.20
34 10 53.37 ± 3.63 35.10 ± 12.04 0.52 ± 0.28
35 9 47.51 ± 3.16 45.25 ± 10.70 0.40 ± 0.13
36 16 56.73 ± 3.30 33.43 ± 8.64 0.36 ± 0.06
37 8 51.81 ± 3.67 20.65 ± 10.72 0.83 ± 0.28
38 8 45.31 ± 5.37 29.18 ± 9.20 0.58 ± 0.10
39 8 59.23 ± 4.21 32.22 ± 10.57 1.06 ± 0.17
40 7 65.03 ± 8.39 20.96 ± 13.27 1.00
41 11 62.03 ± 4.72 4.63 ± 9.50 2.54 ± 0.60
42 6 54.00 ± 6.06 -3.90 ± 13.61 0.76 ± 0.16
43 3 58.90 ± 14.08 9.50 ± 16.35 2.43 ± 0.84
44 5 56.30 ± 2.48 -3.15 ± 13.87 1.19 ± 0.30
45 7 49.00 ± 4.31 14.12 ± 8.52 1.97 ± 0.55
46 4 63.55 ± 6.81 0.54 ± 27.84 3.85 ± 1.13
47 7 53.47 ± 7.80 0.30 ± 14.37 1.22 ± 0.29
48 5 46.66 ± 3.11 7.07 ± 12.65 1.75 ± 0.40
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clamping, in particular the cell-attached configuration to
maintain the intactness of intracellular signaling mecha-
nisms, namely the natriuretic peptide receptor (NPR-A,
NPR-B)/cGMP/protein kinase G (PKG) signaling cascade.
The fascinating findings with both BNP and CNP on basal
sKATP activity, together with their inhibitory effects on
pinacidil evoked sKATP currents (Figs. 4, 5), appear to
illustrate a novel mechanism of NPR-A and NPR-B regu-
lation of sKATP in the heart. It is well known that natriuretic
peptides play key roles in the cardiovascular adaptation to
both acute and chronic pathological insult. The complexity
of their fundamental roles as key mediators in multiple
body systems, beyond the regulation of blood volume, is
well documented, and it appears that the regulation of
sKATP in the myocardium is an extension of this axis.
Saegusa and colleagues demonstrated that ANP secretion
from mechanically stretched mouse isolated atria was
markedly enhanced in preparations taken from Kir6.2
deficient mice compared to wild type [38]. Speculatively,
they suggested that sKATP could play a compensatory role
in protecting the heart under pathological conditions.
However, under physiological conditions, it could control
stretch-induced ANP secretion via a negative feedback
loop [38]. In a previous study, the sulphonylurea receptor
ligand diazoxide, a KATP opener, was shown to inhibit
stretch-induced ANP release in atrial cardiomyocytes [23],
thus supporting the findings of Saegusa and colleagues
[38].
BNP and CNP are agonists for different receptor-linked
pGCs, namely NPR-A and NPR-B, respectively, and that
both are capable of generating the second messenger
cGMP. The fact that both BNP and ANP bind to the same
receptor with the former having comparably lower affinity
raises the possibility that the negative modulatory effects
seen with BNP on KATP function can be recapitulated by
ANP. Indeed Ropero and colleagues showed that ANP
1 nM dampened KATP activity in cell-attached patches
from mouse pancreatic beta cells, illustrated by a 50 %
reduction in NPo compared to no-treatment control [36].
The result obtained in Ropero’s study [36] is consistent
with our findings that BNP and CNP are capable of
inhibiting sKATP activity in rat ventricular cardiomyocytes.
The natriuretic peptides including BNP and CNP have a
high affinity for the clearance receptor NPR-C [37]. Sev-
eral sources of evidence suggest that some of the biological
effects produced by natriuretic peptides are mediated
through NPR-C, with evidence supporting a role for NPR-
C in the hyperpolarization of vascular smooth muscle and
endothelium [10, 44], and its role in CNP regulation of
coronary blood flow and cardioprotection [22]. We sought
to examine the role of NPR-C in natriuretic peptide regu-
lation of sKATP using the NPR-C agonist C-ANF. Inter-
estingly, C-ANF at concentrations C10 nM stimulated
sKATP currents in our patch clamp experiments (Fig. 6).
However, inhibition of pinacidil stimulated KATP currents
was only observed with C-ANF 1 nM. These observations
suggest that BNP and CNP do not elicit sKATP inhibition
via NPR-C agonism.
cGMP as a modulator of KATP
The cGMP analog 8Br-cGMP 10 nM had no appreciable
effect on sKATP openings under normoxic conditions, with
no reduction in sKATP NPo compared to control, however,
caused 50 % inhibition of pinacidil stimulated KATP
openings (Fig. 7). Taking into consideration the results
obtained with 8Br-cGMP, BNP (C10 nM) and CNP
(C0.01 nM), the unexpected and novel inhibitory action of
the natriuretic peptides on cardiac KATP activity may be at
least partially associated with their ability to augment
intracellular cGMP concentrations. However, a recent
study by Chai and co-workers found that 8Br-cGMP
500 lM caused a threefold increase in KATP NPo in cell-
attached patches from rabbit ventricular cardiomyocytes,
Table 1 continued
Treatment Number of cells Unitary conductance (pS) Reversal potential (mV) NPo
49 4 64.65 ± 5.28 5.13 ± 11.65 2.90 ± 0.76
50 5 55.60 ± 4.23 15.95 ± 15.72 1.83 ± 0.50
51 4 63.10 ± 5.64 3.78 ± 7.27 1.71 ± 0.38
52 4 60.98 ± 11.80 29.33 ± 7.09 2.00 ± 0.53
53 6 53.22 ± 3.48 30.34 ± 16.44 3.25 ± 0.88
54 18 52.89 ± 2.55 13.26 ± 7.51 1.00
55 12 57.28 ± 5.52 11.47 ± 6.65 2.92 ± 0.60
56 10 55.78 ± 3.95 33.65 ± 8.67 0.72 ± 0.11
57 14 47.74 ± 3.05 31.78 ± 12.79 1.53 ± 0.32
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although the representative recordings are somewhat
unconvincing [9]. Furthermore, the concentration of cGMP
used in this study is excessive, and massively in excess of
intracellular cGMP concentration [16]. Interestingly, they
found that the cell-permeable cGMP-phosphodiesterase
inhibitor zaprinast (0.05–50 lM) increased KATP NPo in a
concentration-dependent manner up to 12-fold above
baseline, an effect that was completely blunted by addition
of the PKG inhibitor KT5823 1 lM [9]. Their data show
that cGMP-induced increase in sKATP activity in rabbit
ventricular myocytes is in part PKG dependent. An earlier
study by Han and colleagues examined the effect on NO on
KATP activity in rabbit ventricular cardiomyocytes [20]. In
cell-attached patches stimulated with pinacidil 50 lM,
cumulative application of the NO-donors SNP or SNAP
(0.1–1,000 lM) resulted in a concentration-dependent
increase in KATP Po, an effect that was abolished by the
KATP inhibitor glibenclamide 30 lM [20]. Furthermore,
the potentiating effects of both NO-donors on pinacidil-
induced KATP openings were abrogated by two structurally
different PKG inhibitors Rp-8-Br-PET-cGMPS 10 lM and
Rp-pCPT-cGMP 100 lM [20]. Similar findings were pre-
sented in a latter study, alluding to PKG activation as the
key mechanism by which cGMP and NO-donors activate
KATP [19] Fig. 8.
Taking all these findings into consideration, it appears
that natriuretic peptides and NO have opposing effects on
KATP activity cardiomyocytes, consistent with the differ-
ential effects observed with both autacoids despite gener-
ating the same second messenger [7, 8, 41]. Determining
cGMP concentration following BNP and CNP administra-
tion in our pinacidil-activated preparation would give an
interesting insight into the relationship between natriuretic
peptide signaling and KATP activity. However, limitations
remain using primary cultures of adult rat ventricular heart
tissue that have prevented us from attempting such
Fig. 8 ANP/BNP and CNP bind cell surface receptors called NPR-A
and NPR-B, respectively, which have an intracellular catalytic
domain with guanylyl cyclase activity. NPR-A and NPR-B agonism
leads to the generation of cGMP and activation of PKG. PKG
phosphorylates serine/threonine residues in sKATP causing inhibition.
The effect of NPR-A and NPR-B agonism on sKATP activity is
mimicked by the cGMP analog 8Br-cGMP. C-ANF binds a distinct
receptor devoid of a guanylyl cyclase domain called NPR-C and
through a proposed Gai-PLC-PIP2-DAG mechanism, activates PKC.
PKC phosphorylates serine/threonine residues in sKATP leading to
channel opening and an increase in sKATP activity. The PI3K/Akt/
NOS and NO/sGC/cGMP signaling pathways have been proposed to
interplay with the natriuretic pathway, augmenting natriuretic peptide
generated pools of cGMP. These pools could potentially be respon-
sible for facilitating sKATP inhibition
Basic Res Cardiol (2014) 109:402 Page 13 of 15
123
measurements relating to sufficient tissue, sensitivity to
calcium during the isolation process and phenotypic sta-
bility [11].
Pathophysiological implications
The work described here has been undertaken in cardio-
myocytes examined under standard electrophysiological
conditions (normoxia). The technical limitations of the
approach preclude the examination of natriuretic peptide
effects on KATP under conditions of hypoxia or oxidative
stress relevant to cardiac pathologies such as ischemia–
reperfusion or ischemic cardiomyopathy. KATP is impli-
cated in arrhythmia genesis [15], and mutations in genes
coding for Kir6.2 (KCNJ11) and SUR2 (ABCC9) are
linked to left ventricular hypertrophy and dilated cardio-
myopathy in humans [30]. It will be relevant to attempt to
model these in future studies. Although the concentrations
of BNP and CNP employed in some experiments are many
times higher than picomolar physiological plasma con-
centrations [35], they are very relevant to the interstitial
concentrations in ventricular myocardium, especially in
pathological states [35]. In conditions characterized by left
ventricular dysfunction, such as chronic heart failure,
release of stored BNP is observed (and there is some evi-
dence to suggest CNP also), resulting in myocardial con-
centrations in the nanomolar region [35].
Conclusion
In conclusion, we have shown that BNP and CNP inhibit
sKATP in rat ventricular cardiomyocytes and we believe this to
be a novel NPR-A and NPR-B mechanism of KATP regulation
in the heart, at least under physiological conditions. Exami-
nation of this regulatory mechanism in cardiomyocytes under
conditions of oxygen deprivation and whether there are fun-
damental changes in natriuretic peptide regulation of KATP is
important and warrants future investigation.
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